Research Briefs

Out of “an abundance of caution,” the National Heart, Lung, and Blood Institute (NHLBI) has “paused” CONCERT-HF, a phase 2 trial investigating whether c-kit+ cells, alone or in combination with mesenchymal stem cells, can safely benefit patients with chronic heart failure. The reason? NHLBI says the recent controversy about certain journal articles in cell therapy research have raised concerns, although none of the articles in question are about the CONCERT-HF trial itself